histor
serum
therapi
previous
use
combat
infecti
pathogen
howev
serum
sick
anaphylaxi
limit
broad
applic
advanc
antibodi
engin
technolog
made
feasibl
gener
monoclon
antibodi
diverg
method
antibodi
engin
optim
chapter
summar
latest
develop
engin
antibodi
infecti
diseas
on
destroy
pathogen
without
compris
normal
benefici
microbiom
antibodybas
therapi
infecti
diseas
new
far
serum
immunoglobulin
use
neutral
bacteri
virul
later
serum
therapi
appli
wide
rang
infecti
diseas
meningococc
mening
pneumococc
pneumonia
streptococc
scarlet
fever
varicella
measl
pandem
spanish
influenza
ebola
viru
diseas
well
cytomegaloviru
howev
advers
reaction
serum
sick
anaphylaxi
harm
efficaci
serum
therapi
discoveri
antibiot
serum
therapi
infecti
pathogen
quickli
declin
antibiot
therapi
soon
becam
mainstay
bacteri
infect
treatment
howev
success
last
long
emerg
antibioticresist
pathogen
failur
develop
new
antibiot
differ
mechan
action
trap
patient
super
drugresist
bacteria
besid
individu
compromis
immun
antimicrobi
chemotherapi
provid
less
effect
treatment
obvious
antibiot
ineffect
elimin
virus
emerg
antibiot
resist
call
renew
effort
among
mani
option
monoclon
antibodi
mab
may
altern
reminisc
success
applic
antitoxin
fight
meningococc
mening
preantibiot
era
inde
nebacumab
first
human
therapeut
mab
review
regulatori
agenc
engin
treatment
sepsi
gramneg
bacteremia
howev
chess
centocor
efficaci
septic
shock
trial
conduct
usa
found
nonstatist
signific
increas
mortal
monoclon
antiendotoxin
antibodi
nebacumab
placebo
group
patient
gramneg
bacteremia
lead
withdraw
nebacumab
current
two
human
antibodi
palivizumab
raxibacumab
approv
infecti
diseas
mani
engin
antibodi
infecti
pathogen
develop
chapter
summar
exist
technolog
antibodi
engin
optim
discoveri
antibiot
convalesc
serum
first
effect
strategi
combat
infecti
pathogen
diphtheria
tetanu
hepat
b
varicella
cytomegaloviru
et
al
later
discov
mechan
behind
predominantli
due
neutral
activ
effector
function
immunoglobulin
serum
antibodi
deriv
immun
sera
polyclon
natur
howev
problem
lottolot
variat
immun
respons
animalderiv
antibodi
contribut
reduc
efficaci
serum
therapi
besid
prepar
serum
product
expens
laborintens
complic
togeth
discoveri
antibiot
limit
applic
serum
therapi
infecti
pathogen
nevertheless
earli
attempt
open
possibl
antibodybas
therapi
infecti
diseas
year
wit
develop
monoclon
antibodi
mous
hybridoma
technolog
innov
make
possibl
produc
larg
quantiti
antibodi
defin
specif
vitro
pave
way
use
therapeut
monoclon
antibodi
treat
differ
diseas
exampl
xoma
corp
berkeley
calif
igm
antibodi
produc
hybridoma
technolog
design
neutral
endotoxin
lipopolysaccharid
compon
outer
membran
mutant
echerichia
coli
inconclus
result
gener
clinic
trial
led
withdraw
antiendotoxin
mab
p
mous
monoclon
antibodi
limit
shorthalf
life
circul
inabl
trigger
human
effector
function
gener
human
antimous
antibodi
hama
respons
attempt
reduc
immunogen
therapeut
antibodi
effort
direct
produc
antibodi
use
antibodi
engin
technolog
teng
et
al
gener
human
monoclon
igm
antibodi
fuse
human
immun
b
lymphocyt
heteromyeloma
cell
design
fight
gramneg
bacteremia
shock
bind
specif
lipid
domain
endotoxin
clinic
trial
show
overal
benefit
signific
improv
surviv
rate
subgroup
patient
common
advers
event
hypersensit
allerg
reaction
children
meningococc
septic
shock
treat
occur
low
rate
tradit
hybridoma
technolog
gener
antibodi
high
immunogen
therapeut
antibodi
vivo
invok
hama
respons
attenu
immunogen
sever
approach
present
reduc
nonhuman
fragment
antibodi
fig
mani
strategi
recombin
dna
method
use
attenu
human
immun
respons
reduc
level
nonhuman
fragment
mab
chimer
antibodi
produc
replac
mous
constant
region
human
constant
region
gener
antibodi
mous
variabl
region
human
constant
region
perceiv
less
immunogen
mous
monoclon
antibodi
nonetheless
human
antimous
respons
still
exist
use
chimer
antibodi
minim
mous
compon
antibodi
murinederiv
cdr
loop
respons
antigen
bind
graft
human
variabledomain
framework
caution
note
replac
often
chang
structur
relationship
cdr
framework
region
fr
addit
chang
cdr
loop
may
influenc
bind
properti
human
ab
thu
addit
molecul
engin
need
restor
bind
capac
human
antibodi
cdr
graft
method
success
use
gener
human
antibodi
abl
evok
immun
effector
function
adcc
phagocytosi
effect
howev
murinederiv
cdr
loop
still
evok
immun
respons
patient
minim
antiidiotyp
respons
vivo
sever
strategi
exploit
case
part
entir
cdr
residu
involv
antibodyantigen
complex
residu
locat
region
high
variabl
design
specificitydetermin
residu
sdr
graft
murinederiv
sdr
onto
framework
human
antibodi
gener
human
antibodi
minim
immunogen
howev
strategi
need
identif
sdr
besid
structur
featur
target
antibodi
preserv
residu
involv
vlvh
contact
also
preserv
consider
taken
sdr
graft
strategi
usual
gener
antibodi
reduc
antigenbind
capac
thu
addit
vitro
molecul
engin
need
enhanc
antigenbind
affin
framework
shuffl
anoth
human
approach
synthes
combinatori
librari
compris
cdr
nonhuman
antibodi
fuse
frame
pool
synthet
human
germlin
framework
correspond
librari
screen
antibodi
specif
bind
properti
approach
simpl
without
requir
prior
antibodi
structur
knowledg
cdr
analysi
framework
design
lazar
et
al
came
new
paradigm
term
human
string
content
hsc
reduc
immunogen
potenti
approach
base
metric
antibodi
human
compar
nonhuman
sequenc
human
germlin
gene
repertoir
divers
substitut
given
variabl
heavi
light
chain
score
hsc
target
sequenc
human
maxim
hsc
superhuman
use
human
mous
antibodi
method
reli
comparison
cdr
first
hypervari
loop
mice
compar
human
variabl
sequenc
human
similar
ident
mice
select
within
select
gene
share
highest
homolog
mice
sequenc
use
construct
human
antibodi
use
approach
antibodi
design
antigenbind
specif
neutral
activ
gener
although
sever
human
antibodi
approv
market
extent
human
antibodi
still
elicit
human
antihuman
antibodi
haha
respons
exampl
patient
receiv
adalimumab
treatment
effect
treatment
rheumatoid
arthriti
period
time
lost
initi
respons
adalimumab
due
format
haha
besid
human
antibodi
labor
intens
compris
complex
procedur
includ
sequenc
analysi
develop
engin
technolog
assess
bind
properti
evalu
haha
respons
therefor
develop
fulli
human
antibodi
long
pursuit
sever
technolog
includ
display
technolog
transgen
anim
immort
b
cell
transchromosom
calv
avail
gener
fulli
human
antibodi
vitro
display
technolog
among
commonli
use
method
fulli
human
antibodi
gener
advantag
vitro
display
technolog
overcom
immunolog
toler
gener
antibodi
defin
antigen
specif
phage
yeast
display
system
best
exemplifi
display
system
ribosom
bacteria
viru
display
also
use
display
repertoir
singlechain
variabl
antibodi
fragment
scfv
antigenbind
fragment
fab
domain
antibodi
dab
surfac
techniqu
mainli
contain
three
step
amplifi
human
immunoglobulin
variabl
region
deriv
human
b
cell
antibodi
librari
clone
plasmid
transform
transfect
host
cell
construct
surfac
display
vector
desir
antibodi
isol
pan
librari
target
antigenepitop
antibodi
nt
bind
antigen
wash
away
binder
retain
correspond
gene
variabl
region
clone
whole
human
igg
express
vector
express
ortholog
mammalian
system
gener
human
mab
huse
et
al
first
introduc
lambda
phagebas
system
express
collect
function
antibodi
fragment
escherichia
coli
howev
labori
distribut
librari
agar
plate
besid
method
assess
repertoir
roughli
less
natur
antibodi
repertoir
individu
later
progress
achiev
area
display
technolog
extend
librari
size
quantiti
theodor
et
al
produc
mab
west
nile
viru
wnv
e
protein
yeast
surfac
display
vitro
studi
show
one
mab
could
neutral
differ
strain
wnv
anim
experi
demonstr
efficaci
mab
wnv
administ
mab
mous
model
wnv
infect
differ
display
system
may
differ
antibodi
fold
effici
posttransl
modif
epitop
access
may
gener
antibodi
differ
bind
properti
exampl
bowley
et
al
compar
yeast
display
phage
display
use
immun
scfv
cdna
librari
select
antigen
result
show
yeast
display
system
gener
full
scfv
phage
display
system
besid
yeast
display
system
produc
mani
novel
antibodi
mani
display
platform
includ
phage
display
ribosom
display
yeast
display
et
al
among
display
system
phage
displaybas
select
often
prefer
gener
fulli
human
antibodi
display
method
use
complementari
method
display
technolog
becom
standard
method
gener
antibodi
high
affin
howev
drawback
antigen
must
known
prior
order
select
antibodi
high
affin
anoth
strategi
gener
human
mab
use
human
immunoglobulin
transgen
mice
develop
embryon
stem
cell
gene
transfer
method
transgen
mice
gener
carri
human
immunoglobulin
gene
transgen
mice
normal
humor
immun
respons
b
cell
produc
human
antibodi
harvest
immun
transgen
mice
clone
either
hybridoma
vitro
combinatori
librari
antibodi
obtain
via
transgen
mice
good
antigenbind
properti
low
immunogen
three
main
transgen
mice
platform
includ
xenomous
humab
mous
velocimous
howev
flaw
may
exist
use
transgen
mice
method
immun
toler
may
aris
use
immun
antigen
highli
homolog
mous
thu
immun
antibodi
screen
need
transgen
mice
use
gener
human
antibodi
infecti
pathogen
includ
bacteria
viru
exampl
coughlin
et
al
gener
human
monoclon
antibodi
sever
acut
respiratori
syndrom
coronaviru
sarscov
use
xenomous
paul
et
al
gener
human
mab
immun
human
velocimmun
mice
gener
mab
specif
p
aeruginosa
pcrv
protect
murin
infect
model
p
aeruginosa
challeng
memori
b
cell
produc
infect
vaccin
antigen
specif
b
cell
could
persist
lifetim
thu
memori
b
cell
use
sourc
human
mab
immort
epstein
barr
viru
ebv
antigenspecif
b
cell
cultur
secret
larg
amount
antibodi
surfac
immunoglobulin
ebvimmort
b
cell
use
select
antigenspecif
b
cell
fluorescenceactiv
cell
sort
fac
traggiai
e
et
al
use
method
isol
human
monoclon
antibodi
sarscov
found
one
antibodi
exert
effect
protect
vivo
select
antibodi
hcv
hiv
cmv
ebvimmort
b
cell
also
report
produc
human
antibodi
ebvimmort
b
cell
limit
low
effici
ebvimmort
limit
overcom
discoveri
tlr
agonist
increas
effici
ebv
bcell
immort
promot
clone
immort
b
cell
ebvimmort
b
cell
becom
interest
shortcut
gener
human
monoclon
antibodi
isol
memori
b
cell
donor
infect
vaccin
infecti
pathogen
transchromosom
calv
recent
use
produc
largeamount
human
mab
transfer
mammalian
artifici
chromosom
vector
carri
human
ig
loci
bovin
primari
fetal
fibroblast
produc
clone
transchromosom
tc
calv
clone
tc
calv
contain
high
rate
artifici
chromosom
posit
cell
ig
loci
transfer
cell
undergo
rearrang
diversif
express
secret
immunoglobulin
circul
detect
product
tc
cattl
limit
mitot
instabl
human
microchromosom
differ
immunophysiolog
cattl
human
immunospot
array
assay
chip
isaac
rapid
effici
method
gener
antibodi
singl
cell
method
use
microarray
chip
whose
surfac
coat
antibodi
immunoglobulin
trap
antibodysecret
cell
acss
acss
cultur
chip
sever
hour
antibodi
secret
acss
bind
label
antigen
form
circular
spot
easili
identifi
antigenspecif
asc
retriev
obtain
antibodi
cdna
obtain
antibodi
cdna
insert
express
vector
transfect
cell
express
secret
antibodi
detect
elisa
assay
jin
et
al
appli
system
produc
human
mab
virus
within
week
demonstr
isaac
altern
strategi
human
mab
gener
tradit
vitro
monoclon
antibodi
engin
technolog
labori
depend
highthroughput
screen
immort
b
cell
reddi
et
al
develop
new
method
antibodi
isol
bypass
antibodi
screen
use
next
gener
sequenc
bioinformat
analysi
analys
variablegen
repertoir
bone
marrow
plasma
cell
found
variabl
region
immunoglobulin
deriv
immun
mice
becam
highli
polar
highthroughput
dna
sequenc
enabl
identifi
sever
abund
v
l
v
h
gene
sequenc
rapidli
v
l
v
h
gene
rel
frequenc
within
repertoir
pair
synthes
oligonucleotid
pcr
assembl
singlechain
variabl
fragment
fulllength
igg
express
express
system
antibodi
produc
method
antigen
specif
nextgener
sequenc
also
appli
sequenc
singl
antibodysecret
b
cell
dekoski
et
al
use
nextgener
sequenc
technolog
identifi
larg
number
v
h
v
l
singl
b
cell
repertoir
first
isol
singl
b
cell
tetanu
toxoid
immun
human
deposit
b
cell
highdens
microwel
plate
mrna
captur
revers
transcrib
rtpcr
sequenc
inform
transcript
analyz
nextgener
sequenc
technolog
wine
et
al
combin
nextgener
sequenc
technolog
mass
spectrometri
deconvolut
polyclon
serum
respons
immun
sequenc
cdna
deriv
desir
b
lymphocyt
gener
databas
uniqu
v
gene
roch
sequenc
serum
igg
pepsindigest
obtain
f
ab
antigen
specif
f
ab
fragment
purifi
standard
antigenaffin
chromatographi
analyz
bottomup
liquid
chromatographyhighresolut
tandem
mass
spectrometri
map
peptid
mark
uniqu
v
h
sequenc
method
use
identifi
set
vgene
constitut
serum
polyclon
respons
singl
b
cell
defin
subpopul
isol
fac
fulllength
variabl
region
gene
transcript
obtain
amplifi
rtpcr
vitro
antibodi
subsequ
gener
eukaryot
express
system
engin
antibodi
enter
circul
would
elimin
proteolysi
renal
elimin
hepat
elimin
well
neonat
fc
receptormedi
endocytosi
prolong
serum
circul
engin
antibodi
sever
strategi
propos
extend
serum
halflif
therapeut
antibodi
could
reduc
number
applic
dose
attach
highli
flexibl
hydrophil
molecul
polyethylen
glycol
peg
could
increas
hydrodynam
volum
engin
antibodi
increas
volum
thu
improv
serum
halflif
care
attent
paid
number
size
peg
label
may
decreas
activ
bind
affin
engin
antibodi
differ
coupl
method
includ
random
sitedirect
approach
exist
sitedirect
approach
may
better
method
conjug
singl
peg
chain
antibodi
fuse
human
serum
albumin
engin
antibodi
provid
altern
way
extend
serum
halflif
antibodi
bind
site
albumin
fcrn
alter
affin
antigen
affin
fcrn
coval
linkag
albumin
achiev
either
chemic
coupl
genet
engin
method
albumin
igg
taken
cell
macropinocytosi
bind
fcrn
earli
endosom
bind
protect
igg
degrad
lysosom
compart
antibodi
redirect
plasma
membran
releas
back
blood
human
may
hamper
affin
antibodi
sometim
affin
engin
antibodi
may
satisfi
actual
need
affin
optim
therefor
desir
affin
optim
method
depend
optim
cdr
residu
target
random
mutagenesi
use
gener
librari
variant
normal
librari
individu
cdr
clone
screen
improv
bind
antigen
yang
et
al
success
gener
high
affin
human
antibodi
human
envelop
glycoprotein
satur
mutagenesi
cdr
fab
fragment
display
select
improv
bind
immobil
among
cdr
residu
residu
often
concentr
affin
optim
specul
key
variant
region
play
major
role
antigen
affin
mainli
reason
region
locat
center
antibodi
combin
site
therapeut
efficaci
antibodi
directli
influenc
affin
antibodi
pathogen
howev
effector
function
mediat
fc
domain
also
modul
efficaci
antibodi
fc
domain
play
import
role
opsonophagocyt
kill
activ
toxin
neutral
effici
addit
fc
domain
involv
mediat
effector
function
name
complementdepend
cytotox
cdc
antibodydepend
cellmedi
cytotox
adcc
antibodydepend
cell
phagocytosi
adcp
optim
affin
fc
domain
fc
receptor
altern
increas
efficaci
therapeut
antibodi
sever
approach
includ
alanin
scan
sitedirect
mutagenesi
comput
structurebas
design
selectionbas
method
avail
improv
affin
fc
receptor
besid
nlink
glycan
fc
region
igg
also
influenc
interact
fc
region
receptor
antibodi
defici
fucos
attach
asn
link
carbohydr
show
improv
bind
affin
receptor
sever
differ
method
use
modul
fucos
content
igg
differ
express
platform
may
gener
antibodi
differ
fucos
content
exampl
igg
produc
rat
hybridoma
technolog
often
low
fucos
content
yeastand
plantbas
system
produc
antibodi
quit
differ
glycosyl
pattern
antibodi
igg
isotyp
prolong
circul
fcrnmediat
recycl
research
show
mutat
fc
domain
may
increas
affin
fc
receptor
acid
ph
instead
neutral
ph
incorpor
mutat
fc
domain
igg
extend
halflif
antibodi
five
major
class
immunoglobulin
igg
iga
igd
ige
igm
among
igg
class
prefer
develop
therapeut
antibodi
igg
contain
four
isotyp
main
differ
igg
isotyp
locat
fc
domain
date
approv
human
mab
mainli
palivizumab
synagi
medimmun
inc
approv
rsv
infect
human
monoclon
antibodi
prefer
reason
induc
robust
cell
kill
activ
activ
variou
effector
cell
chosen
therapeut
backbon
weak
effector
function
need
sever
therapeut
antibodi
either
market
clinic
develop
howev
dimer
occur
vivo
natur
indepth
analysi
cleav
recombin
suggest
cy
residu
hing
involv
format
coval
dimer
besid
reduc
environ
vivo
facilit
format
dimer
mechan
dimer
exact
structur
dimer
yet
investig
report
disulfid
linkag
interconvert
vivo
may
shed
light
dimer
format
one
consequ
dimer
enhanc
antibodi
avid
may
play
better
protect
role
dimer
exist
low
level
vivo
specul
role
magnifi
less
chosen
backbon
therapeut
antibodi
sever
reason
first
account
minor
compon
igg
human
secondli
suscept
proteolysi
short
halflif
day
vivo
final
display
extens
polymorph
within
constant
domain
ca
nt
activ
classic
complement
pathway
effect
reduc
effector
function
besid
antibodi
exchang
halfmolecul
vivo
form
undesir
crosslink
abrog
halfmolecul
exchang
elimin
possibl
unseen
advers
effect
ser
pro
mutat
introduc
antibodi
engin
optim
therapeut
antibodi
mutat
reduc
halfmolecul
chang
larg
extent
also
extend
serum
halflif
bispecif
antibodi
bsab
two
differ
bind
specif
enabl
simultan
recogn
two
differ
mediatorspathway
exert
import
role
pathogenesi
dual
bind
capac
increas
target
specif
redirect
specif
immun
cell
pathogen
infect
cell
thu
enhanc
pathogen
elimin
recent
bispecif
antibodi
pseudomona
aeruginosa
gener
design
bind
psi
pcrv
psi
extracellular
polysaccharid
involv
immun
evas
biofilm
format
pcrv
take
part
secret
virul
factor
anim
studi
show
bind
psi
pcrv
led
superior
protect
activ
clinic
candid
treatment
p
aeruginosa
berg
et
al
construct
bispecif
antibodi
link
one
heavylight
chain
pair
antibodi
cytotox
cell
heavi
chain
whose
variabl
region
replac
sequenc
construct
antibodi
dual
bind
specif
one
arm
bind
cytotox
cell
arm
contain
sequenc
bind
viral
envelop
protein
hiv
thu
bispecif
antibodi
redirect
cytotox
cell
hivinfect
cell
whose
surfac
express
integr
viral
protein
elimin
pathogen
bispecif
antibodi
hold
great
promis
elimin
hbv
bacteriophag
pathogen
format
bispecif
antibodi
roughli
divid
two
categori
igglik
molecul
nonigglik
molecul
fig
diverg
approach
use
engin
bispecif
antibodi
era
antibiot
resist
antibodybas
therapi
hold
great
promis
treat
infecti
pathogen
holi
grail
produc
human
antibodi
high
therapeut
efficaci
therapeut
potenti
antibodi
deriv
less
immunogen
proper
serum
circul
time
high
antigenbind
affin
exquisit
specif
robust
effector
function
advanc
antibodi
engin
technolog
make
possibl
produc
antibodi
tailor
differ
infect
pathogen
past
decad
magic
bullet
obtain
fruit
success
wide
rang
diseas
includ
tumor
autoimmun
diseas
inflammatori
condit
howev
field
infect
gap
preclin
research
clinic
applic
mani
engin
antibodi
still
make
way
preclinicalclin
test
approv
market
provid
review
technolog
antibodi
engin
optim
optimist
applic
engin
antibodi
treat
infecti
pathogen
emerg
new
infecti
pathogen
multidrug
resist
bacteri
engin
antibodi
may
offer
anoth
choic
combat
threat
